VT-ART-PVentricular Tachycardia Ablation and Radiotherapy for Improved Heart Function
Stereotactic Body Radiation Therapy (SBRT)
Cardiac Conduction System Disease+5
+ Arrhythmias, Cardiac
+ Cardiovascular Diseases
Treatment Study
Summary
Study start date: November 26, 2024
Actual date on which the first participant was enrolled.This study aims to explore new treatment options for patients suffering from ventricular tachycardia, a condition where the heart beats faster than normal. The research focuses on using a combination of heart procedures and radiotherapy to potentially reduce the number of fast heartbeat episodes. This study is important because it may help decrease the need for medications used to control heart rhythms, improve heart function, and enhance the overall quality of life for patients living with this condition. Understanding these potential benefits is crucial for developing better treatment strategies for those affected by ventricular tachycardia. Participants in the study will undergo a series of initial tests to ensure they meet the study requirements. These tests include an ECG, an ultrasound of the heart, a chest CT scan, and various blood tests. The study will last for 60 months and involves 52 patients. Although participants will not incur any costs or receive any payment, there are some risks, such as inflammation around the heart, lung issues, worsening heart failure, or even death. However, there is hope that participants will experience fewer episodes of fast heartbeats, a reduction or complete stop of heart rhythm drugs, improved heart function, and a better quality of life. The study is carefully designed to gather valuable information that could lead to advancements in treating ventricular tachycardia.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.52 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Secondary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location
Policlinico Universitario Agostino Gemelli IRCSS
Rome, ItalyOpen Policlinico Universitario Agostino Gemelli IRCSS in Google Maps